Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria

Clinical trial NCT00055198 · TERMINATED

Trial details

NCT number: NCT00055198
Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Gram-Positive Bacterial Infections

Start date: 2002-12-19
Primary completion: 2004-01-26
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.